Read the official press release published on GlobeNewswire announcing the appointment of biologics manufacturing leader Darryl Sampey, Ph.D., to KOMO Biosciences’ Scientific Advisory Board. Explore the company’s strategic vision to scale the KOMbine™ platform for global therapeutic demands.
Featured on FinancialContent’s market network, KOMO Biosciences’ latest expansion of its Scientific Advisory Board with Dr. Darryl Sampey underscores the commercial viability of its genomic platform. Check out the financial network’s coverage on how this move reinforces KOMO’s asset value and industrial scale potential.
Reported by StreetInsider, KOMO Biosciences’ appointment of Dr. Darryl Sampey to its Scientific Advisory Board signals strong corporate and scientific momentum. Click to read the full financial media coverage on how this strategic addition strengthens KOMO’s market positioning in advanced therapy manufacturing.
Covered by TMCNet, KOMO Biosciences’ latest appointment of Darryl Sampey, Ph.D., to the Scientific Advisory Board highlights the company’s commitment to tech scalability. Read the full release to explore how KOMO is building the industrial infrastructure necessary to bring high-efficiency gene integration to mass market therapeutics.
Featured in FirstWord Pharma’s “People News,” KOMO Biosciences’ recruitment of elite biotechnology talent continues to gain industry recognition. See how the addition of Darryl Sampey, Ph.D., to the Scientific Advisory Board reinforces KOMO’s rising profile in the synthetic biology space.
To support the next phase of its high-efficiency gene integration platform, KOMO Biosciences is leveraging elite manufacturing expertise. The addition of Dr. Darryl Sampey to the Scientific Advisory Board reinforces KOMO’s commitment to bridging cutting-edge genomic engineering with scalable, commercial-grade bioprocessing.
KOMO Biosciences is proud to welcome Darryl Sampey, Ph.D., a seasoned leader in bioprocess development and biologics manufacturing, to its Scientific Advisory Board. Dr. Sampey’s deep expertise will be instrumental as KOMO scales its high-efficiency KOMbine™ platform for advanced therapeutic applications.
The versatility of KOMO’s high-efficiency site-specific integrase technology is now being applied to plant science. Through a new partnership, Syngenta will evaluate the KOMbine™ platform to drive innovation in maize genome engineering, marking a strategic milestone in KOMO’s growth beyond human therapeutics.
KOMO Biosciences is expanding its reach into agricultural biotechnology through a research evaluation license agreement with Syngenta. This collaboration will explore the application of KOMO’s high-efficiency KOMbine™ platform for site-specific gene integration in maize, aiming to accelerate the development of high-performing, sustainable crops.
